GenomOncology is the leading provider of software solutions for the precision oncology market. 


Review our latest Press Releases, Publications, and Blog Posts to see how we are helping researchers and clinicians enhance their workflow, scale their reporting capabilities, and improve patients lives everyday. 

We are continuously improving our solutions to fit the evolving needs of our clients.


September 29, 2020

The University of Alabama at Birmingham (UAB) Selects GenomOncology's Pathology Workbench and GenomAnalytics for Molecular Pathology Lab Expansion

GenomOncology announced today that The University of Alabama at Birmingham (UAB) has selected GenomOncology's Pathology Workbench and GenomAnalytics to help scale their molecular pathology lab's test volume and analysis.

May 20, 2020

The Pancreatic Cancer Action Network Implements Genomoncology’s Clinical Trial Matching Solution to Support Biomarker-Driven Clinical Trial Searches

Patient advocacy organization, Pancreatic Cancer Action Network (PanCAN) and healthcare software company GenomOncology, LLC announce PanCAN’s implementation of GenomOncology’s Clinical Trial Matching solution that will streamline the organization’s biomarker-driven clinical trial matching process as part of their Patient Services program.

April 8, 2020

Hawaii Pathologists' Laboratory selects GenomOncology's Pathology Workbench for new Precision Medicine program

GenomOncology, LLC announced today that the Hawaii Pathologists' Laboratory (HPL) has selected the GenomOncology Pathology Workbench to provide analysis services for the assay for their new Precision Medicine program.

Nov 7, 2019

GenomOncology Precision Oncology Platform to be implemented at Nationally Recognized Academic Medical Center

GenomOncology, LLC (GO) announced today that it was selected by the Duke Cancer Institute to utilize GO's Precision Oncology Platform to provide real-time therapeutic, prognostic, and clinical trial recommendations to molecular tumor board organizers and participants at Duke Cancer Institute. 

July 12, 2019

Improved website for

My Cancer Genome launched

Vanderbilt-Ingram Cancer Center and GenomOncology LLC announce the launch of the newly redesigned and improved My Cancer Genome website. The new site showcases the breadth and depth of curated content from My Cancer Genome.

June 6, 2019

GenomOncology announces participation in Biden Cancer Initiative’s OCTIC

GenomOncology is excited to be a part of the Biden Cancer Initiative’s Oncology Clinical Trial Information Commons (OCTIC), joining forces with 8 other organizations to improve clinical trial matching and enrollment for patients.

May 2, 2019

Northwestern Memorial Healthcare Chooses GenomOncology Pathology Workbench for their NGS Clinical Analysis

GenomOncology announces Northwestern Memorial Healthcare has chosen the GenomOncology Pathology Workbench system as part of its clinical analysis process for their latest Oncomine Comprehensive NGS Assay. The Pathology Workbench enables comprehensive variant filtering and flexible reporting to help scale Northwestern's process.


26, 2018

GenomOncology Announces Brad Wertz as Chairman and CEO

GenomOncology announced today that Brad Wertz will assume the role of Chairman and Chief Executive Officer (CEO) as of January 1, 2019. Mr. Wertz has been a founding investor and chairman of the board since the company's...


28, 2018

GenomOncology Enables Novel Decision Support for AML at the Nashville Veterans Affairs Hospital

GenomOncology LLC, a leading provider of end-to-end precision medicine solutions in oncology, has developed a solution to integrate IHC, FISH, NGS and Karyotyping in order to provide therapy and clinical trial recommendations...


23, 2018

GenomOncology Announces GO Pathology Workbench in use by Emory Healthcare 

GenomOncology today announced that Emory Healthcare is now using GenomOncology's GO Pathology Workbench system as part of its clinical reporting process, enabling the return of clinical reports to ordering physicians more rapidly...


23, 2018

GenomOncology adds Jonathan Seaton, former SVP Corporate & Business Development At Illumina, to its Board Of Directors

GenomOncology LLC, a leading provider of end-to-end precision medicine solutions in oncology, has added Jonathan Seaton most recently Senior Vice President for Corporate & Business Development at Illumina to its Board of Directors.


07, 2018

Fluidigm Partners with GenomOncology to Provide a Comprehensive Immuno-oncology Gene Expression Solution

Fluidigm Corporation (NASDAQ:FLDM) and GenomOncology today announced an expanded Immuno-Oncology Gene Expression Workflow to accelerate the development of checkpoint immunotherapies and the identification of potential predictive biomarker signatures for therapeutic...


1138 West 9th St Suite 400

Cleveland, OH 44113, USA

(440) 617-6087


© 2020 GenomOncology LLC